Candel Therapeutics, Inc. (CADL) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2022
Loading P/E history...
CADL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Candel Therapeutics, Inc. (CADL) trades at a price-to-earnings ratio of -11.6x, with a stock price of $8.35 and trailing twelve-month earnings per share of $-0.16.
The current P/E is 130% below its 5-year average of 38.5x. Over the past five years, CADL's P/E has ranged from a low of 5.2x to a high of 71.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, CADL trades at a 152% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, CADL trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CADL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CADL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 4.0Lowest | -Best | +307%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CADL Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $1.79 | $0.35 | 5.2x | -87% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $3.14 | $0.04 | 71.9x | +87% |
Average P/E for displayed period: 38.5x
See CADL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CADL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CADL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCADL — Frequently Asked Questions
Quick answers to the most common questions about buying CADL stock.
Is CADL stock overvalued or undervalued?
CADL trades at -11.6x P/E, below its 5-year average of 38.5x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CADL's valuation compare to peers?
Candel Therapeutics, Inc. P/E of -11.6x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is CADL's PEG ratio?
CADL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2022.